News
FNA
9.79
-0.71%
-0.07
Weekly Report: what happened at FNA last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at FNA last week (0415-0419)?
Weekly Report · 04/22 09:24
Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA)
Paragon 28, Inc.'s price-to-sales ratio of 3.7x is middle-of-the-road for companies in the Medical Equipment industry in the U.S. Paragon 28 grew revenue by 19% last year and is expected to grow 18% in the next three years. The company's P/S ratio is closely matching its industry peers. But the company's revenue growth isn't enough to justify its high valuation.
Simply Wall St · 04/17 12:56
Weekly Report: what happened at FNA last week (0408-0412)?
Weekly Report · 04/15 09:23
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 04/14 21:56
Weekly Report: what happened at FNA last week (0401-0405)?
Weekly Report · 04/08 09:24
Paragon 28 Price Target Maintained With a $18.00/Share by Stephens & Co.
Dow Jones · 04/05 13:24
Stephens & Co. Reiterates Overweight on Paragon 28, Maintains $18 Price Target
Benzinga · 04/05 13:15
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
TipRanks · 04/05 11:00
Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)
TipRanks · 04/05 09:00
Health Care Sector Update for 04/04/2024: FNA, SLP, ADCT, ALUR
NASDAQ · 04/04 20:03
Unveiling 4 Analyst Insights On Paragon 28
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment. Paragon 28 has an average price target of $17.25 and 12-month price targets of $18.00. 4 analysts have shared their evaluations of paragon 28 during the recent three months. The company has a positive revenue growth rate of 17.58% in the past year.
Benzinga · 04/04 20:00
Maintaining a Buy: Paragon 28’s Strong Q1 Performance and Optimistic Financial Outlook Despite CFO Transition
TipRanks · 04/04 15:15
Paragon 28 Price Target Maintained With a $17.00/Share by Needham
Dow Jones · 04/04 14:54
Paragon 28 gives prelim Q1 numbers, announces CFO transition
Healthcare Paragon 28 gives prelim Q1 numbers, announces CFO transition. The company also said that Stephen Deitsch, CFO, will depart the company on April 5, 2024. Kristina Wright will take over as interim CFO effective April 3, 2024 for the interim period. Preliminary net revenue for Q1 2024 is expected to be $60.8M.
Seeking Alpha · 04/04 14:48
Needham Reiterates Buy on Paragon 28, Maintains $17 Price Target
Benzinga · 04/04 14:44
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Shares of Lamb Weston Holdings, Inc. Tumbled 17.5% to $83.40 on Thursday. The company reported weak third-quarter results and cut its FY24 outlook. The Dow Jones gained over 150 points in Thursday's session. Other big U.S. Stocks also recorded losses.
Benzinga · 04/04 14:44
Analysts’ Top Healthcare Picks: Paragon 28 (FNA), Genmab (GMAB)
TipRanks · 04/04 14:30
Paragon 28 Chief Financial Officer Stephen Deitsch Resigns
Paragon 28's Chief Financial Officer Stephen Deitsch is leaving the medical-device company to take a post with another company. Kristina Wright will serve as interim finance chief while Paragon 28 looks for a successor. Deitsch has been Paragon's chief financial officer since October 2020.
Dow Jones · 04/04 12:15
Paragon 28 Sees CFO Transition, Maintains Revenue Outlook
TipRanks · 04/04 12:12
More
Webull provides a variety of real-time FNA stock news. You can receive the latest news about Paragon 28 Inc through multiple platforms. This information may help you make smarter investment decisions.
About FNA
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.